“ Gain insight into clinically actionable mutations and discover new treatment targets with one of the market’s most comprehensive and affordable panels. ”

The Power of Knowing

BGI SENTIS™ Cancer+Discovery (Tissue/ctDNA)

Introduction

Technological advances combined with improved understanding of the genetic basis of cancer has revolutionized the way we manage cancer. Utilizing patient’s particular genomic profile, clinicians can now assess the risk of hereditary cancer for the patient and patient’s family, as well as tailor the best treatment options.

BGI’s SENTIS™ Cancer+Discovery provides clinicians with one of the market’s most comprehensive and accurate Next Generation Sequencing (NGS) based testing solution for the identification of clinically actionable mutations, as well as discovery of novel variants with important function in cancer. Supporting both tissue sample and liquid biopsy, the panel offers whole exon coverage of 688 cancer-related genes and interrogates most common types of alterations including SNVs, indels, CNVs and fusions in solid tumors.

Advantages

Comprehensive

- Whole exon coverage of 688 cancer-related genes, supporting most common types of genomic alterations including base substitutions, InDel, CNV, fusion,TMB and MSI
- Includes genes associated with both sporadic and hereditary cancers
- Provides interpretation on the therapeutic relevance in 200+ drugs, including 260 targeted therapies (both approved and currently in clinical trial), 11 immunotherapies and 11 commonly used chemotherapies
- Includes 425 genes in cancer-related pathways for discovery of novel pathogenic variants

Flexible

- BGI SENTIS™ Cancer+Discovery (Tissue): matched fresh tissue, biopsy, FFPE, DNA and peripheral blood
- BGI SENTIS™ Cancer+Discovery (ctDNA): peripheral blood or DNA

Reliable

- See technical information for details.

Liquid biopsy version allows genetic profiling in situations where tissue is not available or continuous monitoring of tumor molecular profile is required.

The Power of Knowing

BGI SENTIS™ Cancer+Discovery (Tissue/ctDNA)

Gene Panel Overview



Workflow

Technical Information

SENTIS Cancer+Discovery(Tissue)	Limit of Detection(LoD)	Positive Predicttive Value(PPV)	Sensitivity
Single Nucleotide Variations(SNV)	1%	100%	99.2%
Indels	0.5%	93%	97.8%
Copy Number Amplifications(CNV)	3.4 copies	100%	100%
Splice Variants(SV)	0.5%	100%	100%

SENTIS Cancer+Discovery(ctDNA)	Limit of Detection(LoD)	Positive Predicttive Value(PPV)	Sensitivity
SNV	0.6%	97.30%	98.3%
Indels	0.59%	100%	100%
CNV	3.5 copies	100%	100%
SV	1.25%	100%	100%

Sample Requirements

BGI SENTIS™ Cancer+Discovery (Tissue)

- >60mg tissue or 15 FFPE 10mm*10mm (5-10μm) sections or ≥3 samplings of biopsy or ≥3μg good quality, tumor DNA;
- 5mL of peripheral blood

BGI SENTIS™ Cancer+Discovery (ctDNA)

- ≥10mL of peripheral blood (separated plasma and formed elements) or ≥8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube

Ordering Information

ITEM	CATALOG NO.
BGI SENTIS™ Cancer+Discovery (Tissue)	DX0643
BGI SENTIS™ Cancer+Discovery (ctDNA)	DX0644

Turnaround Time

20 days (from sample arriving at BGI lab to report)

Contact your local BGI representative for more information or email **info@bgi.com**. More information can also be found on our website.

www.bgi.com/global/

For Research Use Only. Not for use in diagnostic procedures.

Testing services not currently available in the United States of America. Please contact a representative for regional availability.